ZA964097B - New variant of apolipoprotein a-i - Google Patents
New variant of apolipoprotein a-iInfo
- Publication number
- ZA964097B ZA964097B ZA964097A ZA964097A ZA964097B ZA 964097 B ZA964097 B ZA 964097B ZA 964097 A ZA964097 A ZA 964097A ZA 964097 A ZA964097 A ZA 964097A ZA 964097 B ZA964097 B ZA 964097B
- Authority
- ZA
- South Africa
- Prior art keywords
- apolipoprotein
- new variant
- variant
- new
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9506061A FR2734568B1 (en) | 1995-05-22 | 1995-05-22 | NEW VARIANTS OF APOLIPOPROTEIN |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA964097B true ZA964097B (en) | 1996-12-06 |
Family
ID=9479241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA964097A ZA964097B (en) | 1995-05-22 | 1996-05-22 | New variant of apolipoprotein a-i |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP0827538A1 (en) |
| JP (1) | JPH11505712A (en) |
| KR (1) | KR19990021828A (en) |
| AU (1) | AU717202B2 (en) |
| BR (1) | BR9608813A (en) |
| CA (1) | CA2218759A1 (en) |
| CZ (1) | CZ291376B6 (en) |
| FR (1) | FR2734568B1 (en) |
| HU (1) | HUP9802926A3 (en) |
| IL (1) | IL118336A0 (en) |
| MX (1) | MX9708727A (en) |
| NO (1) | NO975367L (en) |
| SK (1) | SK156397A3 (en) |
| TW (1) | TW434260B (en) |
| WO (1) | WO1996037608A1 (en) |
| ZA (1) | ZA964097B (en) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6004925A (en) | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6037323A (en) | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6046166A (en) * | 1997-09-29 | 2000-04-04 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6518412B1 (en) | 1997-09-29 | 2003-02-11 | Jean-Louis Dasseux | Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| CA2402772A1 (en) * | 2000-03-13 | 2001-09-20 | Amgen Inc. | Apolipoprotein-a-i regulation of t-cell signalling |
| AU2002213843B2 (en) | 2000-11-10 | 2008-02-07 | F. Hoffmann-La Roche Ltd. | Apolipoprotein analogues |
| US8119590B2 (en) | 2001-09-28 | 2012-02-21 | Cedars-Sinai Medical Center | Prevention and treatment of restenosis by local administration of drug |
| US7223726B2 (en) * | 2002-01-14 | 2007-05-29 | The Regents Of The University Of California | Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same |
| CA2486127C (en) | 2002-05-17 | 2014-03-11 | Esperion Therapeutics, Inc. | Method of treating dyslipidemic disorders |
| ATE538776T1 (en) | 2003-02-14 | 2012-01-15 | Childrens Hosp & Res Ct Oak | CARRIER FOR RELEASE OF LIPOPHILIC ACTIVE INGREDIENTS AND METHOD OF USE THEREOF |
| WO2005097206A2 (en) | 2004-04-06 | 2005-10-20 | Cedars-Sinai Medical Center | Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein a-i and apolipoprotein a-i milano |
| KR100560102B1 (en) | 2004-06-25 | 2006-03-13 | 한국생명공학연구원 | Prophylactic and therapeutic agents containing point mutants of proapolipoprotein A-I for anti-atherosclerosis and anti-hyperlipidemia |
| WO2006012632A2 (en) * | 2004-07-23 | 2006-02-02 | Xencor, Inc. | Apolipoprotein a-1 derivatives with altered immunogenicity |
| KR100725642B1 (en) * | 2006-01-20 | 2007-06-07 | 충남대학교산학협력단 | Peptides of antioxidant activities against low-density lipoprotein LDL |
| EP2026829B1 (en) | 2006-06-01 | 2013-01-09 | Institut de Cardiologie de Montréal | Compound for use in the treatment of valvular stenosis |
| WO2009158678A1 (en) | 2008-06-27 | 2009-12-30 | Children's Hospital & Research Center At Oakland | Lipophilic nucleic acid delivery vehicle and methods of use therefor |
| CA2739464C (en) * | 2008-10-03 | 2020-03-31 | Opko Curna, Llc | Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1 |
| CA2752182C (en) | 2009-02-16 | 2017-11-28 | Cerenis Therapeutics Sa | Apolipoprotein a-i mimics |
| EP3466969B1 (en) | 2011-02-07 | 2024-05-08 | Abionyx Pharma SA | Lipoprotein complexes and manufacturing and use thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9103701D0 (en) * | 1991-12-13 | 1991-12-13 | Kabi Pharmacia Ab | apolipoprotein |
| FR2704556B1 (en) * | 1993-04-30 | 1995-07-13 | Rhone Poulenc Rorer Sa | Recombinant viruses and their use in gene therapy. |
-
1995
- 1995-05-22 FR FR9506061A patent/FR2734568B1/en not_active Expired - Fee Related
-
1996
- 1996-05-20 HU HU9802926A patent/HUP9802926A3/en unknown
- 1996-05-20 EP EP96916216A patent/EP0827538A1/en not_active Withdrawn
- 1996-05-20 IL IL11833696A patent/IL118336A0/en unknown
- 1996-05-20 JP JP8535430A patent/JPH11505712A/en not_active Withdrawn
- 1996-05-20 KR KR1019970708302A patent/KR19990021828A/en not_active Application Discontinuation
- 1996-05-20 MX MX9708727A patent/MX9708727A/en unknown
- 1996-05-20 AU AU59048/96A patent/AU717202B2/en not_active Ceased
- 1996-05-20 CA CA002218759A patent/CA2218759A1/en not_active Abandoned
- 1996-05-20 BR BR9608813A patent/BR9608813A/en not_active Application Discontinuation
- 1996-05-20 SK SK1563-97A patent/SK156397A3/en unknown
- 1996-05-20 WO PCT/FR1996/000747 patent/WO1996037608A1/en not_active Application Discontinuation
- 1996-05-20 CZ CZ19973671A patent/CZ291376B6/en not_active IP Right Cessation
- 1996-05-22 TW TW085106086A patent/TW434260B/en active
- 1996-05-22 ZA ZA964097A patent/ZA964097B/en unknown
-
1997
- 1997-11-21 NO NO975367A patent/NO975367L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU5904896A (en) | 1996-12-11 |
| JPH11505712A (en) | 1999-05-25 |
| KR19990021828A (en) | 1999-03-25 |
| NO975367D0 (en) | 1997-11-21 |
| BR9608813A (en) | 1999-02-17 |
| CZ291376B6 (en) | 2003-02-12 |
| IL118336A0 (en) | 1996-09-12 |
| CA2218759A1 (en) | 1996-11-28 |
| FR2734568B1 (en) | 1997-06-20 |
| HUP9802926A2 (en) | 1999-03-29 |
| WO1996037608A1 (en) | 1996-11-28 |
| CZ367197A3 (en) | 1998-03-18 |
| AU717202B2 (en) | 2000-03-23 |
| TW434260B (en) | 2001-05-16 |
| EP0827538A1 (en) | 1998-03-11 |
| HUP9802926A3 (en) | 2001-08-28 |
| FR2734568A1 (en) | 1996-11-29 |
| NO975367L (en) | 1997-11-21 |
| SK156397A3 (en) | 1998-07-08 |
| MX9708727A (en) | 1997-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA964097B (en) | New variant of apolipoprotein a-i | |
| HK1002864A1 (en) | Water-dissoluble narobomycin ester | |
| AU7885498A (en) | Selective acylation of epsilon-amino groups | |
| PL322277A1 (en) | Derivatives of pyrazol-4-ylobenzoyl | |
| GB9514437D0 (en) | Inhibition of gene expression | |
| GB9514435D0 (en) | Inhibition of gene expression | |
| PL324451A1 (en) | Derivatives of diphenylmethylenepiperidine | |
| PL319905A1 (en) | Apolipoprotein b synthesis inhibitors | |
| ZA96962B (en) | Bisphenol ester derivatives | |
| IL117668A0 (en) | Preparation of polyesters | |
| GB9718518D0 (en) | Fractionation of Hemicellulosic Materials | |
| DE69623258D1 (en) | Copolyetherester | |
| GB9507297D0 (en) | New composition of matter | |
| PL325170A1 (en) | Bipolar forms of throwaflocacin | |
| PL323148A1 (en) | Esters of crabapenemes | |
| HU9503736D0 (en) | New derivatives of trans apovincaminic-acid-esters | |
| PL323141A1 (en) | Esters of crabapenemes | |
| GB9513043D0 (en) | Selection of recombinant molecules | |
| SG64924A1 (en) | Inhibiting photodecompostion of 3-substituted-2- oxindoles | |
| KR0110698Y1 (en) | Suspension of autoseat | |
| HUT75286A (en) | New intermediers of ace-inhibitors | |
| GB9504379D0 (en) | Fractionation of mixtures | |
| ZA962440B (en) | Destressing of railtracks | |
| GB2316947B (en) | Selection of recombinant molecules | |
| GB9525144D0 (en) | Purification of esters |